Non-Small Cell Lung Cancer Market by Type (Squamous Cell Carcinoma, Large Cell Carcinoma, Others and Adenocarcinoma), Treatment Type (Chemotherapy, Targeted Therapy and Immunotherapy), Distribution Channel (Hospital Pharmacy, Drug Store and Retail Pharmacy and Online Pharmacy) and Geography (North America, Europe, APAC and RoW) - Forecast up to 2027
Non-small cell lung cancer is a form of lung cancer, where malignant tumor cells are formed in the lungs. It comprises of a group of different diseases, which behave same as adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Adenocarcinoma is a form of non-small cell lung cancer, which is most usual in women than men and more in young people than old age group of people. The non small cell lung cancer market growth is significantly propelled by surge in the rate of consumption of tobacco more by young group of population, extreme air pollution, and unhealthy lifestyle. Exposure to air comprising traces of metals such as arsenic, asbestos, and others, are key reasons of adenocarcinoma. Therefore, the surge in number of people smoking and following unhealthy lifestyle are few of the leading factors causing non-small cell lung cancer. However, the limited number of skilled professionals will hamper the market growth. The Non-Small Cell Lung Cancer Market is likely to grow at a rate of 9.2% CAGR by 2027.
Non-Small Cell Lung Cancer Market based on Type
Squamous Cell Carcinoma
Large Cell Carcinoma
Others
Adenocarcinoma
Non-Small Cell Lung Cancer Market based on Treatment Type
Chemotherapy
Targeted Therapy
Immunotherapy
Non-Small Cell Lung Cancer Market based on Distribution Channel
Hospital Pharmacy
Drug Store and Retail Pharmacy
Online Pharmacy
Non-Small Cell Lung Cancer Market based on Geography
North America
Europe
Asia Pacific
Rest of the World
On the basis of type the market is divided into Squamous Cell Carcinoma, Large Cell Carcinoma, Others and Adenocarcinoma. In this segmentation, the Adenocarcinoma segment holds the largest share in the non-small cell lung cancer market. The largest share of the segment is ascribed to the high number of people affected by adenocarcinoma and availability of wide range of treatments for this indication.
In terms of treatment type, the non-small cell lung cancer market is majorly segmented into Chemotherapy, Targeted Therapy and Immunotherapy. Among them the targeted therapy category holds the significant share in market. This is due to the specific clinical benefits which this therapy provides, such as low risk of negative effects and the availability of various targeted medicines. Also, more patients are choosing targeted therapy as a cancer treatment option because it is effective in up to 80% of cases.
In terms of distribution channel, the market is categorized into Hospital Pharmacy, Drug Store and Retail Pharmacy and Online Pharmacy. The Hospital Pharmacy segment is likely to have a maximum share in the market growth. This can accredited to the surge in the number of NSCLC patients being admitted to hospitals and the availability of qualified specialists in these settings.
Based on the geographical analysis the non-small cell lung cancer market is segregated into North America, Europe, Asia Pacific and Rest of the World. The North America region is anticipated to have the maximum share in the market. This is because of region's robust concentration of key companies, well-developed healthcare infrastructure, and increased public awareness of the significance of early cancer detection.
Furthermore, the global rise in the cancer cases fuels the global non-small cell lung cancer market over the estimated period. As per the American Cancer Society statistics from 2016, the majority of cases of SCLC occur in people between the ages of 60 and 80, with a worldwide death rate of 30,000 per year. Additionally, as per the WHO data, lung cancer is the second most common type of cancer in men and women, accounting for 1.59 million deaths. This fuels the global market growth.
The leading players of the market are F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Bristol-Myers Squibb Company, Merck & Co., Inc., Novartis AG, Pfizer Inc., Astrazeneca, Celgene Corporation, Sanofi, and boehringer ingelheim
As a result, smoking is the most common habit in the present scenario around the world which is the significant reason for all types of lung cancer. Specifically, smoking is the major reason for non-small cell lung cancer which enhances the scope of the present market.
The report analyzes the geographical highlights in terms of consumption of the product/service within the region also indicates the factors which are affecting the market within each region.
The report consists of opportunities and challenges faced by the players in the global non-small cell lung cancer
The report implies the regional and segmental analysis which is projected to witness the fastest growth.
Provides competitive outlook which includes the market ranking of the key players, coupled with new product launches, partnerships, business expansions, and acquisitions.
Non-Small Cell Lung Cancer Market based on Type
Squamous Cell Carcinoma
Large Cell Carcinoma
Others
Adenocarcinoma
Non-Small Cell Lung Cancer Market based on Treatment Type
Chemotherapy
Targeted Therapy
Immunotherapy
Non-Small Cell Lung Cancer Market based on Distribution Channel
Hospital Pharmacy
Drug Store and Retail Pharmacy
Online Pharmacy
Non-Small Cell Lung Cancer Market based on Geography
North America
Europe
Asia Pacific
Rest of the World
On the basis of type the market is divided into Squamous Cell Carcinoma, Large Cell Carcinoma, Others and Adenocarcinoma. In this segmentation, the Adenocarcinoma segment holds the largest share in the non-small cell lung cancer market. The largest share of the segment is ascribed to the high number of people affected by adenocarcinoma and availability of wide range of treatments for this indication.
In terms of treatment type, the non-small cell lung cancer market is majorly segmented into Chemotherapy, Targeted Therapy and Immunotherapy. Among them the targeted therapy category holds the significant share in market. This is due to the specific clinical benefits which this therapy provides, such as low risk of negative effects and the availability of various targeted medicines. Also, more patients are choosing targeted therapy as a cancer treatment option because it is effective in up to 80% of cases.
In terms of distribution channel, the market is categorized into Hospital Pharmacy, Drug Store and Retail Pharmacy and Online Pharmacy. The Hospital Pharmacy segment is likely to have a maximum share in the market growth. This can accredited to the surge in the number of NSCLC patients being admitted to hospitals and the availability of qualified specialists in these settings.
Based on the geographical analysis the non-small cell lung cancer market is segregated into North America, Europe, Asia Pacific and Rest of the World. The North America region is anticipated to have the maximum share in the market. This is because of region's robust concentration of key companies, well-developed healthcare infrastructure, and increased public awareness of the significance of early cancer detection.
Furthermore, the global rise in the cancer cases fuels the global non-small cell lung cancer market over the estimated period. As per the American Cancer Society statistics from 2016, the majority of cases of SCLC occur in people between the ages of 60 and 80, with a worldwide death rate of 30,000 per year. Additionally, as per the WHO data, lung cancer is the second most common type of cancer in men and women, accounting for 1.59 million deaths. This fuels the global market growth.
The leading players of the market are F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Bristol-Myers Squibb Company, Merck & Co., Inc., Novartis AG, Pfizer Inc., Astrazeneca, Celgene Corporation, Sanofi, and boehringer ingelheim
As a result, smoking is the most common habit in the present scenario around the world which is the significant reason for all types of lung cancer. Specifically, smoking is the major reason for non-small cell lung cancer which enhances the scope of the present market.
The report analyzes the geographical highlights in terms of consumption of the product/service within the region also indicates the factors which are affecting the market within each region.
The report consists of opportunities and challenges faced by the players in the global non-small cell lung cancer
The report implies the regional and segmental analysis which is projected to witness the fastest growth.
Provides competitive outlook which includes the market ranking of the key players, coupled with new product launches, partnerships, business expansions, and acquisitions.
1. EXECUTIVE SUMMARY
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. TYPE: MARKET SIZE & ANALYSIS
5.1. Overview
5.2. Squamous Cell Carcinoma
5.3. Large Cell Carcinoma
5.4. Others
5.5. Adenocarcinoma
6. TREATMENT TYPE: MARKET SIZE & ANALYSIS
6.1. Overview
6.2. Chemotherapy
6.3. Targeted Therapy
6.4. Immunotherapy
7. DISTRIBUTION CHANNEL: MARKET SIZE & ANALYSIS
7.1. Overview
7.2. Hospital Pharmacy
7.3. Drug Store and Retail Pharmacy
7.4. Online Pharmacy
8. GEOGRAPHY: MARKET SIZE & ANALYSIS
8.1. Overview
8.2. North America
8.3. Europe
8.4. Asia Pacific
8.5. Rest of the World
9. COMPETITIVE LANDSCAPE
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. VENDOR PROFILES
10.1. F. Hoffmann-La Roche Ltd
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. Eli Lilly and Company
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. Bristol-Myers Squibb Company
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. Merck & Co., Inc.
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. Novartis AG
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. Pfizer Inc.
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. Astrazeneca
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. Celgene Corporation
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. Sanofi
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. boehringer ingelheim
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy
11. ANALYST OPINION
12. ANNEXURE
12.1. Report Scope
12.2. Market Definitions
12.3. Research Methodology
12.3.1. Data Collation and In-house Estimation
12.3.2. Market Triangulation
12.3.3. Forecasting
12.4. Report Assumptions
12.5. Declarations
12.6. Stakeholders
12.7. Abbreviations
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. TYPE: MARKET SIZE & ANALYSIS
5.1. Overview
5.2. Squamous Cell Carcinoma
5.3. Large Cell Carcinoma
5.4. Others
5.5. Adenocarcinoma
6. TREATMENT TYPE: MARKET SIZE & ANALYSIS
6.1. Overview
6.2. Chemotherapy
6.3. Targeted Therapy
6.4. Immunotherapy
7. DISTRIBUTION CHANNEL: MARKET SIZE & ANALYSIS
7.1. Overview
7.2. Hospital Pharmacy
7.3. Drug Store and Retail Pharmacy
7.4. Online Pharmacy
8. GEOGRAPHY: MARKET SIZE & ANALYSIS
8.1. Overview
8.2. North America
8.3. Europe
8.4. Asia Pacific
8.5. Rest of the World
9. COMPETITIVE LANDSCAPE
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. VENDOR PROFILES
10.1. F. Hoffmann-La Roche Ltd
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. Eli Lilly and Company
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. Bristol-Myers Squibb Company
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. Merck & Co., Inc.
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. Novartis AG
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. Pfizer Inc.
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. Astrazeneca
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. Celgene Corporation
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. Sanofi
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. boehringer ingelheim
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy
11. ANALYST OPINION
12. ANNEXURE
12.1. Report Scope
12.2. Market Definitions
12.3. Research Methodology
12.3.1. Data Collation and In-house Estimation
12.3.2. Market Triangulation
12.3.3. Forecasting
12.4. Report Assumptions
12.5. Declarations
12.6. Stakeholders
12.7. Abbreviations
LIST OF TABLES
TABLE 1. GLOBAL NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 2. GLOBAL NON-SMALL CELL LUNG CANCER MARKET VALUE FOR SQUAMOUS CELL CARCINOMA, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 3. GLOBAL NON-SMALL CELL LUNG CANCER MARKET VALUE FOR LARGE CELL CARCINOMA, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 4. GLOBAL NON-SMALL CELL LUNG CANCER MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 5. GLOBAL NON-SMALL CELL LUNG CANCER MARKET VALUE FOR ADENOCARCINOMA, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 6. GLOBAL NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 7. GLOBAL NON-SMALL CELL LUNG CANCER MARKET VALUE FOR CHEMOTHERAPY, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 8. GLOBAL NON-SMALL CELL LUNG CANCER MARKET VALUE FOR TARGETED THERAPY, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 9. GLOBAL NON-SMALL CELL LUNG CANCER MARKET VALUE FOR IMMUNOTHERAPY, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 10. GLOBAL NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 11. GLOBAL NON-SMALL CELL LUNG CANCER MARKET VALUE FOR HOSPITAL PHARMACY, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 12. GLOBAL NON-SMALL CELL LUNG CANCER MARKET VALUE FOR DRUG STORE AND RETAIL PHARMACY, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 13. GLOBAL NON-SMALL CELL LUNG CANCER MARKET VALUE FOR ONLINE PHARMACY, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 14. NORTH AMERICA NON-SMALL CELL LUNG CANCER MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 15. NORTH AMERICA NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 16. NORTH AMERICA NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 17. NORTH AMERICA NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 18. U.S NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 19. U.S NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 20. U.S NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 21. CANADA NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 22. CANADA NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 23. CANADA NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 24. EUROPE NON-SMALL CELL LUNG CANCER MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 25. EUROPE NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 26. EUROPE NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 27. EUROPE NON-SMALL CELL LUNG CANCER MARKET VALUE, DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 28. GERMANY NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 29. GERMANY NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 30. GERMANY NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 31. U.K NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 32. U.K NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 33. U.K NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 34. FRANCE NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 35. FRANCE NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 36. FRANCE NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 37. ITALY NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 38. ITALY NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 39. ITALY NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 40. SPAIN NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 41. SPAIN NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 42. SPAIN NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 43. ROE NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 44. ROE NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 45. ROE NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 46. ASIA PACIFC NON-SMALL CELL LUNG CANCER MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 47. ASIA PACIFC NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 48. ASIA PACIFC NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 49. ASIA PACIFC NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 50. CHINA NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 51. CHINA NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 52. CHINA NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 53. INDIA NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 54. INDIA NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 55. INDIA NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 56. JAPAN NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 57. JAPAN NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 58. JAPAN NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 59. REST OF APAC NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 60. REST OF APAC NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 61. REST OF APAC NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 62. REST OF WORLD NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 63. REST OF WORLD NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 64. REST OF WORLD NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 65. F. HOFFMANN-LA ROCHE LTD: FINANCIALS
TABLE 66. F. HOFFMANN-LA ROCHE LTD: PRODUCTS & SERVICES
TABLE 67. F. HOFFMANN-LA ROCHE LTD: RECENT DEVELOPMENTS
TABLE 68. ELI LILLY AND COMPANY: FINANCIALS
TABLE 69. ELI LILLY AND COMPANY: PRODUCTS & SERVICES
TABLE 70. ELI LILLY AND COMPANY: RECENT DEVELOPMENTS
TABLE 71. BRISTOL-MYERS SQUIBB COMPANY: FINANCIALS
TABLE 72. BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS & SERVICES
TABLE 73. BRISTOL-MYERS SQUIBB COMPANY: RECENT DEVELOPMENTS
TABLE 74. MERCK & CO., INC.: FINANCIALS
TABLE 75. MERCK & CO., INC.: PRODUCTS & SERVICES
TABLE 76. MERCK & CO., INC.: RECENT DEVELOPMENTS
TABLE 77. NOVARTIS AG: FINANCIALS
TABLE 78. NOVARTIS AG: PRODUCTS & SERVICES
TABLE 79. NOVARTIS AG: RECENT DEVELOPMENTS
TABLE 80. PFIZER INC.: FINANCIALS
TABLE 81. PFIZER INC.: PRODUCTS & SERVICES
TABLE 82. PFIZER INC.: RECENT DEVELOPMENTS
TABLE 83. ASTRAZENECA: FINANCIALS
TABLE 84. ASTRAZENECA: PRODUCTS & SERVICES
TABLE 85. ASTRAZENECA: RECENT DEVELOPMENTS
TABLE 86. CELGENE CORPORATION: FINANCIALS
TABLE 87. CELGENE CORPORATION: PRODUCTS & SERVICES
TABLE 88. CELGENE CORPORATION: RECENT DEVELOPMENTS
TABLE 89. SANOFI: FINANCIALS
TABLE 90. SANOFI: PRODUCTS & SERVICES
TABLE 91. SANOFI: RECENT DEVELOPMENTS
TABLE 92. BOEHRINGER INGELHEIM: FINANCIALS
TABLE 93. BOEHRINGER INGELHEIM: PRODUCTS & SERVICES
TABLE 94. BOEHRINGER INGELHEIM: RECENT DEVELOPMENTS
TABLE 1. GLOBAL NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 2. GLOBAL NON-SMALL CELL LUNG CANCER MARKET VALUE FOR SQUAMOUS CELL CARCINOMA, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 3. GLOBAL NON-SMALL CELL LUNG CANCER MARKET VALUE FOR LARGE CELL CARCINOMA, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 4. GLOBAL NON-SMALL CELL LUNG CANCER MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 5. GLOBAL NON-SMALL CELL LUNG CANCER MARKET VALUE FOR ADENOCARCINOMA, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 6. GLOBAL NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 7. GLOBAL NON-SMALL CELL LUNG CANCER MARKET VALUE FOR CHEMOTHERAPY, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 8. GLOBAL NON-SMALL CELL LUNG CANCER MARKET VALUE FOR TARGETED THERAPY, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 9. GLOBAL NON-SMALL CELL LUNG CANCER MARKET VALUE FOR IMMUNOTHERAPY, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 10. GLOBAL NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 11. GLOBAL NON-SMALL CELL LUNG CANCER MARKET VALUE FOR HOSPITAL PHARMACY, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 12. GLOBAL NON-SMALL CELL LUNG CANCER MARKET VALUE FOR DRUG STORE AND RETAIL PHARMACY, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 13. GLOBAL NON-SMALL CELL LUNG CANCER MARKET VALUE FOR ONLINE PHARMACY, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 14. NORTH AMERICA NON-SMALL CELL LUNG CANCER MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 15. NORTH AMERICA NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 16. NORTH AMERICA NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 17. NORTH AMERICA NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 18. U.S NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 19. U.S NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 20. U.S NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 21. CANADA NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 22. CANADA NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 23. CANADA NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 24. EUROPE NON-SMALL CELL LUNG CANCER MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 25. EUROPE NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 26. EUROPE NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 27. EUROPE NON-SMALL CELL LUNG CANCER MARKET VALUE, DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 28. GERMANY NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 29. GERMANY NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 30. GERMANY NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 31. U.K NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 32. U.K NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 33. U.K NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 34. FRANCE NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 35. FRANCE NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 36. FRANCE NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 37. ITALY NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 38. ITALY NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 39. ITALY NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 40. SPAIN NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 41. SPAIN NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 42. SPAIN NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 43. ROE NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 44. ROE NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 45. ROE NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 46. ASIA PACIFC NON-SMALL CELL LUNG CANCER MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 47. ASIA PACIFC NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 48. ASIA PACIFC NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 49. ASIA PACIFC NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 50. CHINA NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 51. CHINA NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 52. CHINA NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 53. INDIA NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 54. INDIA NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 55. INDIA NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 56. JAPAN NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 57. JAPAN NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 58. JAPAN NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 59. REST OF APAC NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 60. REST OF APAC NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 61. REST OF APAC NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 62. REST OF WORLD NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 63. REST OF WORLD NON-SMALL CELL LUNG CANCER MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 64. REST OF WORLD NON-SMALL CELL LUNG CANCER MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 65. F. HOFFMANN-LA ROCHE LTD: FINANCIALS
TABLE 66. F. HOFFMANN-LA ROCHE LTD: PRODUCTS & SERVICES
TABLE 67. F. HOFFMANN-LA ROCHE LTD: RECENT DEVELOPMENTS
TABLE 68. ELI LILLY AND COMPANY: FINANCIALS
TABLE 69. ELI LILLY AND COMPANY: PRODUCTS & SERVICES
TABLE 70. ELI LILLY AND COMPANY: RECENT DEVELOPMENTS
TABLE 71. BRISTOL-MYERS SQUIBB COMPANY: FINANCIALS
TABLE 72. BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS & SERVICES
TABLE 73. BRISTOL-MYERS SQUIBB COMPANY: RECENT DEVELOPMENTS
TABLE 74. MERCK & CO., INC.: FINANCIALS
TABLE 75. MERCK & CO., INC.: PRODUCTS & SERVICES
TABLE 76. MERCK & CO., INC.: RECENT DEVELOPMENTS
TABLE 77. NOVARTIS AG: FINANCIALS
TABLE 78. NOVARTIS AG: PRODUCTS & SERVICES
TABLE 79. NOVARTIS AG: RECENT DEVELOPMENTS
TABLE 80. PFIZER INC.: FINANCIALS
TABLE 81. PFIZER INC.: PRODUCTS & SERVICES
TABLE 82. PFIZER INC.: RECENT DEVELOPMENTS
TABLE 83. ASTRAZENECA: FINANCIALS
TABLE 84. ASTRAZENECA: PRODUCTS & SERVICES
TABLE 85. ASTRAZENECA: RECENT DEVELOPMENTS
TABLE 86. CELGENE CORPORATION: FINANCIALS
TABLE 87. CELGENE CORPORATION: PRODUCTS & SERVICES
TABLE 88. CELGENE CORPORATION: RECENT DEVELOPMENTS
TABLE 89. SANOFI: FINANCIALS
TABLE 90. SANOFI: PRODUCTS & SERVICES
TABLE 91. SANOFI: RECENT DEVELOPMENTS
TABLE 92. BOEHRINGER INGELHEIM: FINANCIALS
TABLE 93. BOEHRINGER INGELHEIM: PRODUCTS & SERVICES
TABLE 94. BOEHRINGER INGELHEIM: RECENT DEVELOPMENTS
